New and Old Antiepileptic Drugs

  • James J. Cereghino


Interdisciplinary workers have focused in previous chapters on mechanisms of seizure development in man and laboratory models, metabolic aspects of epileptogenesis, and anatomical pathways and cellular mechanisms associated with seizure spread. While much is known about prevention and suppression of seizures, the ultimate physiological and biochemical action of antiepileptic drugs (AEDs) is not known. This chapter will focus on the information available for researchers developing new drugs both in the laboratory and in the clinic.


Antiepileptic Drug Partial Seizure Barbituric Acid Pharmaceutical Firm Maximal Electroshock Seizure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Locock, C. Discussion of paper by Sieveking, E. Analysis of 52 cases of epilepsy observed by the author. Lancet 1: 528, 1857.Google Scholar
  2. 2.
    Hammond, W. and Cross, T. Clinical Lectures on Diseases of the Nervous System. New York: D. Appleton and Company, 1874.Google Scholar
  3. 3.
    Hauptmann, A. Luminal bei epilepsie. Munch. Med. Wochenschr. 59: 1907–1909, 1912.Google Scholar
  4. 4.
    Weese, H. Pharmacologie des Prominal. Dtsch. Med. Wochenschr. 58: 696, 1932.CrossRefGoogle Scholar
  5. 5.
    Marce, M. Sur l’action toxique de l’essence d’absinthe. CR Acad. Sci. (D) (Paris) 58: 628–629, 1864.Google Scholar
  6. 6.
    Fritsch, G. and Hitzig, E. Ueber die elecktrische erregbarkeit des grosshirns. Arch. Anat. Physiol. Wissenseh. Med. 37: 300–332, 1870.Google Scholar
  7. 7.
    Browne, J. On the actions of pictrotoxin and the antagonism between picrotoxin and chloral hydrate. Br. Med. J. 1: 409–411, 1875.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Bert, P. La Pression Barometrique. English translation by M. Hitchcock and F. Hitchcock. Columbus, Ohio: College Book Co., 1943.Google Scholar
  9. 9.
    Albertoni, P. Untersuchung uber die Wirkung einiger Arzneimittel auf die Erregbarkest des Grosshirns nebst Beitragen zur Therapie der Epilepsie. Arch. Exp. Pathol. Pharmackol. 15: 248–288, 1882.Google Scholar
  10. 10.
    Putnam, T. and Merritt, H. Experimental determination of the anticonvulsant properties of some phenyl derivatives. Science 85: 525–526, 1937.PubMedCrossRefGoogle Scholar
  11. 11.
    Merritt, H. and Putnam, T. Sodium diphenylhydantoinate in treatment of convulsive disorders. J.A.M.A., 111: 1068–1073, 1938.Google Scholar
  12. 12.
    Federal Food and Drug Act of 1906. Public Law 384, 59th Congress.Google Scholar
  13. 13.
    Merritt, H. and Putnam, T. Experimental determination of anticonvulsant activity of chemical compounds. Epilepsia (Series II ) 3: 51–75, 1945.CrossRefGoogle Scholar
  14. 14.
    Everett, G. and Richards, R. Comparative anticonvulsive action of 3,5,5-trimethyloxazolidine-2,4-dione (Tridione), Dilantin and phenobarbital. J. Pharmacol. Exp,. Ther. 81: 402–407, 1944.Google Scholar
  15. 15.
    Richards, R. and Everett, G. Analgesic and anticonvulsive properties of 3,5,5-trimethyloxazolidine-2,4-dione (Tridione). Fed. Proc. 3: 39, 1944.Google Scholar
  16. 16.
    Federal Food, Drug, and Cosmetic Act of 1938. Public Law 717, 75th Congress.Google Scholar
  17. 17.
    Drug Amendments Act of 1962. Public Law 87-781, 21 USC 355Google Scholar
  18. 18.
    Cereghino, J. and Penry, J.. General Principles. Testing of anticonvulsants in man. In: Antiepileptic Drugs, D. Woodbury, J. Penry, R. Schmidt (eds). New York: Raven Press, pp. 63–73, 1972.Google Scholar
  19. 19.
    Cereghino, J. and Penry, J. General Principles. Testing of antiepileptic drugs in humans. In: Antiepileptic Drugs Second Edition, D. Woodbury, J. Penry, C. Pippenger (eds). New York: Raven Press, pp. 141–157, 1982.Google Scholar
  20. 20.
    Gruber, C., Jr., Brock, J., Dyken, M. Comparison of the effectiveness of phenobarbital, mephobarbital, primidone, diphenylhydantoin, metharbital and methylphenylethylhydantoin in motor seizures. Clin. Pharmacol. Ther. 3. 23–28, 1961.Google Scholar
  21. 21.
    Symposium on Laboratory Evaluation of Antiepileptic Drugs, Salt Lake City, Utah, May 13–14, 1968. Epilepsia 10: 101–335, 1969.Google Scholar
  22. 22.
    Woodbury, D., Penry, J., Schmidt, R. (eds). Antiepileptic Drugs. New York: Raven Press, 1972.Google Scholar
  23. 23.
    Purpura, D., Penry, J., Tower, D., Woodbury, D., Walter, R. (eds). Experimental Models of EpilepsyA Manual for the Laboratory Worker. New York: Raven Press, 1972.Google Scholar
  24. 24.
    Glaser, G., Penry, J., Woodbury, D. (eds). Antiepileptic Drugs Mechanisms of Action. New York: Raven Press, 1980.Google Scholar
  25. 25.
    FDA. Isocarboxazid; drugs for human use; Drug Efficacy Study Implementation; permission for drugs to remain on the market; amendment. Fed. Register 44: 5040950410, 1979.Google Scholar
  26. 26.
    FDA. Chapter I, Food and Drug Administration, Department of Health, Education, and Welfare. Subchapter D-Drugs for human use. Part 314-New Drug Application. Part 320Bioavailability and bioequivalence requirement. Fed. Register 44: 1624–1653, 1977.Google Scholar
  27. 27.
    Porter, R., Cereghino, J., Gladding, G., Hessie, B., Kupferberg, H., Scoville, B., White, B. Antiepileptic Drug Development Program. Cleve. Clin. Q. 51: 293–305, 1984.CrossRefGoogle Scholar
  28. 28.
    Schmidt, R. Discussion of paper by J. Millichap, Relation of laboratory evaluation to clinical effectiveness of antiepileptic drugs. In: Symposium on Laboratory Evaluation of Antiepileptic Drugs, Salt Lake City, Utah, May 13–14, 1968. Epilepsia 10:326–328, 1969.Google Scholar
  29. 29.
    Meldrum, B. Preclinical test systems for evaluation of novel compounds. In: Current Problems in Epilepsy: New Anticonvulsant Drugs. B.S. Meldrum, RJ. Porter (eds). London: John Libbey, pp. 31–48, 1986.Google Scholar
  30. 30.
    Wada, J. (ed). Kindling 3. New York: Raven Press, 1986.Google Scholar
  31. 31.
    Olsen, R and Venter, J. (eds). Benzodiazepine/GABA Receptors and Chloride Channels. Structural and Functional Properties. New York: Alan R. Liss, Inc., 1986.Google Scholar
  32. 32.
    Bartholini, G., Bossi, L., Lloyd, K., Morselli, P. (eds). Epilepsy and GABA Receptor Agonists. Basic and Therapeutic Research. New York: Raven Press, 1986.Google Scholar
  33. 33.
    Leppik, I., Dreifuss, F., Bowman, T., Santilli, N., Jacobs, M., Crosby, C., Cloyd, J., Stockman, J., Graves, N., Sutula, T., Welty, T., Vickery, J., Brundage, R., Gumnit, R., Gutierres, A. A double-blind crossover evaluation of progabide in partial seizures. Neurology 35 (Suppl 1): 285, 1985.Google Scholar
  34. 34.
    Schmidt, D. and Utech, K. Progabide for refractory partial epilepsy: A controlled add-on trial. Neurology 36: 217–221, 1986.PubMedCrossRefGoogle Scholar
  35. 35.
    Treiman, D., Wilensky, A., Ben-Menachem, E., Ojemann, L., Yerby, M., Barber, K., McCormick, K. Efficacy of Nafimidone in the treatment of intractable partial seizures: Report of a multicenter pilot study. Neurology 34 (Suppl 1): 266, 1984.Google Scholar
  36. 36.
    Treiman, D., Kupferberg, H., Ben-Menachem, E., Barber, K., Chelberg, R., Gunawan, S. Inhibition of the metabolism of carbamazepine and its metabolites by Nafimidone, a new antiepileptic drug. Neurology 35 (Suppl 1): 285, 1985.Google Scholar
  37. 37.
    Treiman, D., Ben-Menachem, E., Barber, K., Gunawan, S., Chelberg, R. Pharmacokinetics of Nafimidone, a new antiepileptic drug (AED), in patients with epilepsy. Neurology 35 (Suppl 1): 286, 1985.Google Scholar
  38. 38.
    Donofrio, P., Sackellares, C., Madsen, J., Matsuo, F., Abou-Khalil, B., Berent, S., Wagner, J., Ater, S., Mayor, H., Gay, P., Rollins, D., Tolman, K., White, B., Sato, S. Pilot study of fluzinamide (N-methyl-3–3-(trifluoromethyl) phenoxy -1-azetidinecarboxamide) in refractory partial seizures. Neurology 35: 1239–1241, 1985.PubMedCrossRefGoogle Scholar
  39. 39.
    Sackellares, J., Donofrio, P., Abou-Khalil, B., Berent, S., Madsen, J., Matsuo, F., Ater, S., Tolman, K., White, B., Sato, S. Pilot study of Fluzinamide (N-methyl-33-(trifluoromethyl)phenoxyl-azetidinearboxamine) in refractory partial seizures. Neurology 34 (Suppl 1): 265–266, 1984.Google Scholar
  40. 40.
    Fuerst, R., Graves, N., Leppik, I., Remmel, R., Rosenfeld, W., Sierzant, T. A preliminary report on alteration of carbamazepine and phenytoin metabolism by felbamate. Drug Intell. Clin. Pharm. 20: 465, 1986.Google Scholar
  41. 41.
    Kapetanovic, I., Yonekawa, W., Kupferberg, H., Cos, L., Rollins, D., Tolman, K. Single and multiple dose kinetics of a new antiepileptic drug, Org 6370, and its desmethyl metabolite, Org 6363. Ther. Drug Monit. 8: 140–144, 1986.PubMedCrossRefGoogle Scholar
  42. 42.
    Holmes, B., Brogden, R., Heel, R., Speight, T., Avery, G. Flunarizine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs 27: 6–44, 1984.PubMedCrossRefGoogle Scholar
  43. 43.
    Kapetanovic, I., Kupferberg, H., Torchin, C., Pitlick, W., Treiman, D. Pharmacokinetics of flunarizine, (E)-1-Bis (4-fluorophenyl) methyl-4-(3-phenyl-2propenyl) piperzine, in epileptic patients. Acta Pharmacol. Toxicol. (Copenh.), Suppl V: 108, 1986.Google Scholar
  44. 44.
    Treiman, D., DeGiorgio, C., Cornish, J., Cereghino, J. Efficacy and toxicity of flunarizine in partial onset seizures at serum concentrations of 30, 60, and 120 ng/ml. Epilepsia 27: 649–650, 1986.CrossRefGoogle Scholar
  45. 45.
    Treiman, D., DeGiorgio, C., Kapetanovic, I., Kupferberg, H. Single-dose and steady-state pharmacokinetics of flunarizine in epileptic patients. Epilepsia 27: 649, 1986.CrossRefGoogle Scholar
  46. 46.
    Goldberg, M. Potential antiepileptic drugs. Eterobarb: absorption, distribution, biotransformation, and excretion. In: Antiepileptic Drugs Second Edition. D. Woodbury, J. Penry, C. Pippenger (eds). New York: Raven Press, pp. 141–157, 1982.Google Scholar
  47. 47.
    Mattson, R. Potential antiepileptic drugs. Eterobarb: clinical aspects. In: Antiepileptic Drugs Second Edition, D. Woodbury, J. Penry, C. Pippenger (eds). New York: Raven Press, pp. 141–157, 1982.Google Scholar
  48. 48.
    Browne, T., Fromm, G., Howard, G., Leppik, I., Matthews, J., McLean, J., Penry, J. Terrence, C. Multicenter double-blind study of efficacy and safety of Zonisamide (CI-912) in the treatment of medically refractory tonic-clonic seizures. Neurology 36 (Suppl 1): 325, 1986.Google Scholar
  49. 49.
    Sackellares, J., Wilder, B., Ramsay, R., Browne, T., Abou-Khalil,.B., Berent, S., Guterman, A., Howard, G., Wagner, J. Double-blind, placebo-controlled clinical trial of Zonisamide in complex partial seizures. Neurology 36 (Suppl 1): 85, 1986.Google Scholar
  50. 50.
    U.S. Food and Drug Administration. “Peripheral and Central Nervous System Drugs Advisory Committee. Transcript of Meeting #16, May 18, 1984, Rockville, MD.Google Scholar
  51. 51.
    U.S. Food and Drug Administration. “Peripheral and Central Nervous System Drugs Advisory Committee. Transcript of Meeting #17, October 18, 1985, Rockville, MD.Google Scholar
  52. 52.
    Ben-Menachem, E., Schechter, P., Haegele, K., Mumford, J., Persson, L. Pharmacokinetics of Vigabatrin (Gamma Vinyl GABA) and GABA as revealed by repeated plasma and CSF sampling. Neurology 36 (Suppl 1): 325, 1986.Google Scholar
  53. 53.
    Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 22: 489–501, 1981.CrossRefGoogle Scholar
  54. 54.
    Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for classification of epilepsies and epileptic syndromes. Epilepsia 26: 268–278, 1985.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1988

Authors and Affiliations

  • James J. Cereghino
    • 1
  1. 1.Chief Epilepsy BranchNational Institute of Neurological and Communicative Disorders and StrokeBethesdaUSA

Personalised recommendations